Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Convertible Debt (2023)

Mereo BioPharma (MREO) has disclosed Convertible Debt for 1 consecutive years, with $4.4 million as the latest value for Q4 2023.

  • On a quarterly basis, Convertible Debt changed N/A to $4.4 million in Q4 2023 year-over-year; TTM through Dec 2023 was $4.4 million, a N/A change, with the full-year FY2023 number at $4.4 million, changed N/A from a year prior.
  • Convertible Debt was $4.4 million for Q4 2023 at Mereo BioPharma.
  • In the past five years, Convertible Debt ranged from a high of $4.4 million in Q4 2023 to a low of $4.4 million in Q4 2023.